全文获取类型
收费全文 | 1650篇 |
免费 | 130篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 57篇 |
妇产科学 | 30篇 |
基础医学 | 267篇 |
口腔科学 | 13篇 |
临床医学 | 222篇 |
内科学 | 340篇 |
皮肤病学 | 18篇 |
神经病学 | 134篇 |
特种医学 | 53篇 |
外科学 | 152篇 |
综合类 | 19篇 |
一般理论 | 2篇 |
预防医学 | 177篇 |
眼科学 | 35篇 |
药学 | 91篇 |
中国医学 | 2篇 |
肿瘤学 | 161篇 |
出版年
2023年 | 13篇 |
2022年 | 17篇 |
2021年 | 27篇 |
2020年 | 13篇 |
2019年 | 17篇 |
2018年 | 22篇 |
2017年 | 23篇 |
2016年 | 20篇 |
2015年 | 20篇 |
2014年 | 44篇 |
2013年 | 64篇 |
2012年 | 106篇 |
2011年 | 88篇 |
2010年 | 56篇 |
2009年 | 48篇 |
2008年 | 83篇 |
2007年 | 75篇 |
2006年 | 72篇 |
2005年 | 102篇 |
2004年 | 85篇 |
2003年 | 82篇 |
2002年 | 105篇 |
2001年 | 44篇 |
2000年 | 62篇 |
1999年 | 42篇 |
1998年 | 22篇 |
1997年 | 22篇 |
1996年 | 16篇 |
1995年 | 11篇 |
1994年 | 16篇 |
1993年 | 14篇 |
1992年 | 35篇 |
1991年 | 29篇 |
1990年 | 26篇 |
1989年 | 31篇 |
1988年 | 28篇 |
1987年 | 12篇 |
1986年 | 16篇 |
1985年 | 9篇 |
1984年 | 8篇 |
1983年 | 9篇 |
1981年 | 11篇 |
1980年 | 10篇 |
1979年 | 8篇 |
1978年 | 10篇 |
1977年 | 10篇 |
1973年 | 7篇 |
1972年 | 7篇 |
1969年 | 8篇 |
1968年 | 10篇 |
排序方式: 共有1782条查询结果,搜索用时 11 毫秒
41.
Juanita Westbury Karin Beld Shane Jackson Gregory Peterson 《Australasian journal on ageing》2010,29(2):72-76
Aim: To examine psychotropic medication review practices in residential aged care facilities. Methods: Psychotropic medicine use data were collected from residents from 40 residential aged care facilities throughout Tasmania. As an indication of review practices, the measure was repeated at 33 of the original facilities a year later. Results: A total of 2389 residents' medication records were examined in 2006. Regular doses of antipsychotics and benzodiazepines were taken by 42% and 21% of residents, respectively. Medication data were available for 1307 of the residents in 2007. Over 60% were taking the same antipsychotic or benzodiazepine agent, at the same dose in 2007, as they were in 2006. Dosage reduction or cessation occurred in less than a quarter of the residents. Conclusion: The utilisation of psychotropic medication is high in Tasmanian residential aged care facilities. Attempts to reduce psychotropic doses happen infrequently. Further research is required to establish the barriers to appropriate psychotropic medication review in this setting. 相似文献
42.
43.
44.
Mycotic aneurysms of coronary arteries 总被引:2,自引:0,他引:2
45.
Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? 总被引:2,自引:0,他引:2
Crook ED Thallapureddy A Migdal S Flack JM Greene EL Salahudeen A Tucker JK Taylor HA 《The American journal of the medical sciences》2003,325(6):340-348
Dyslipidemia is a cardiovascular disease (CVD) risk factor that is associated with enhanced atherosclerosis and plaque instability. Renal insufficiency is associated with abnormalities in lipoprotein metabolism in both the early and the advanced stages of chronic renal failure. These include alterations in apolipoprotein A (apo A)- and B- containing lipoproteins, high-density lipoproteins, and triglycerides. In animal models, these alterations in lipid metabolism and action lead to macrophage activation and infiltration in the kidney with resultant tubulointerstitial and endothelial cell injury. Limited data in humans suggest that, in addition to contributing to CVD, dyslipidemia may be a risk factor for the progression of renal disease. The effects of dyslipidemia on the kidney are mainly observed in those with other risk factors for renal disease progression such as hypertension, diabetes, and proteinuria. Renal disease is a strong risk factor for CVD and African Americans have high rates of renal disease. Therefore, examining the effects of dyslipidemia on the development or progression or renal disease will be an important question for the Jackson Heart Study and is the topic of this review. 相似文献
46.
David Crook Raymond Bruce Melek Worthington Dayid Mulcahy MRCP David Patterson FRCP Victor Wynn FRCP 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》1992,6(6):633-639
Summary Changes in plasma concentrations of high density lipoproteins (HDL) and triglycerides may partly explain the ability of cholesterol-lowering drugs to decrease the incidence of coronary heart disease. We measured the response of fasting plasma lipids, lipoproteins, and apolipoproteins in 46 subjects with Type IIa hypercholesterolemia treated with simvastatin for 3 months. The initial dose of simvastatin (10 mg/day) was subsequently increased up to 40 mg/day if the plasma cholesterol concentration had not fallen below 5.2 mmol/l. Plasma concentrations of HDL cholesterol and of the apolipoproteins AI and AII were increased by simvastatin. The increase in HDL cholesterol (9%) was due to increases in both subfractions (HDL2 17%; HDL3 7%), changes that would be consistent with a beneficial effect on cardiovascular risk. Simvastatin decreased plasma triglyceride concentrations by 25%. Plasma total cholesterol concentrations fell by 35% after 3 months of treatment; this fall was proportional to the initial concentration and was due almost entirely to a 45% fall in low density lipoprotein cholesterol. In contrast, plasma concentrations of lipoprotein Lp(a) were not affected by simvastatin. 相似文献
47.
48.
Samantha J. Broyd Lisa-marie Greenwood Rodney J. Croft Anna Dalecki Juanita Todd Patricia T. Michie Stuart J. Johnstone Nadia Solowij 《International journal of psychophysiology》2013
Chronic cannabis use has been associated with neurocognitive deficits, alterations in brain structure and function, and with psychosis. This study investigated the effects of chronic cannabis use on P50 sensory-gating in regular users, and explored the association between sensory gating, cannabis use history and the development of psychotic-like symptoms. Twenty controls and 21 regular cannabis users completed a P50 paired-click (S1 and S2) paradigm with an inter-pair interval of 9 s. The groups were compared on P50 amplitude to S1 and S2, P50 ratio (S2/S1) and P50 difference score (S1–S2). While cannabis users overall did not differ from controls on P50 measures, prolonged duration of regular use was associated with greater impairment in sensory gating as indexed by both P50 ratio and difference scores (including after controlling for tobacco use). Long-term cannabis users were found to have worse sensory gating ratios and difference scores compared to short-term users and controls. P50 metrics did not correlate significantly with any measure of psychotic-like symptoms in cannabis users. These results suggest that prolonged exposure to cannabis results in impaired P50 sensory-gating in long-term cannabis users. While it is possible that these deficits may have pre-dated cannabis use and reflect a vulnerability to cannabis use, their association with increasing years of cannabis use suggests that this is not the case. Impaired P50 sensory-gating ratios have also been reported in patients with schizophrenia and may indicate a similar underlying pathology. 相似文献
49.
Steven Tisseverasinghe Marina Marbán Juanita Crook David Petrik Cynthia Araujo 《Brachytherapy》2021,20(4):849-856
PURPOSE/OBJECTIVE Permanent seed Low-Dose-Rate brachytherapy is planned and delivered using transrectal ultrasound (TRUS). Post-implant evaluation for quality assurance is usually performed using Computed Tomography (CT). Registration of the CT images with MRI reduces subjectivity in contouring by improving prostate edge detection. We hypothesized that a set of TRUS images post procedure may provide the same benefit.MATERIAL/METHODS Consecutive patients undergoing Low-Dose-Rate prostate brachytherapy were recruited. TRUS images were recorded under anesthesia at completion of their implant. In addition, all patients underwent standard post-implant quality assurance including prostate CT and MRI at day 30. These were co-registered, contoured and seeds were identified. Three independent observers contoured and registered the post implant TRUS images to the Day 30 CT using seed matching. Prostate volumes and dosimetric parameters were compared through Intraclass Correlation Coefficient (ICC) to evaluate the concordance between MRI and ultrasound (US).RESULTS 26 patients were recruited from 10/17 to 01/18. Mean prostate volume was 34.5 (SD 10.8) cm3 at baseline on planning TRUS images, 37.4 (SD 11.3) cm3 on Day 0 post implant TRUS and 36.7 (SD 11.7) cm3 on Day 30 MRI. D90 was 112.6% (SD 9.3) on CT-MRI and 112.9% (SD 11.1) on CT-US. V100 was 94.6% (SD 3.8) for CT-MRI, 95.1% (SD 4.3) for CT-US. Student t-tests were used to compare groups. No significant differences were noted.CONCLUSION Post implant TRUS may be useful for quality assurance for post-implant dosimetry particularly if access to an MRI is limited. 相似文献
50.
Claire Zhang Michelle Hilts Deidre Batchelar Nathan Orlando Lori Gardi Aaron Fenster Juanita Crook 《Brachytherapy》2021,20(1):248-256
PurposePermanent breast seed implant (PBSI) brachytherapy is a novel technique for early-stage breast cancer. Computed tomography (CT) images are used for treatment planning and freehand 2D ultrasound for implant guidance. The multimodality imaging approach leads to discrepancies in target identification. To address this, a prototype 3D ultrasound (3DUS) system was recently developed for PBSI. In this study, we characterize the 3DUS system performance, establish QA baselines, and develop and test a method to register 3DUS images to CT images for PBSI planning.Methods and Materials3DUS system performance was characterized by testing distance and volume measurement accuracy, and needle template alignment accuracy. 3DUS-CT registration was achieved through point-based registration using a 3D-printed model designed and constructed to provide visible landmarks on both images and tested on an in-house made gel breast phantom.ResultsThe 3DUS system mean distance measurement accuracy was within 1% in axial, lateral, and elevational directions. A volumetric error of 3% was observed. The mean needle template alignment error was 1.0° ± 0.3 ° and 1.3 ± 0.5 mm. The mean 3DUS-CT registration error was within 3 mm when imaging at the breast centre or across all breast quadrants.ConclusionsThis study provided baseline data to characterize the performance of a prototype 3DUS system for PBSI planning and developed and tested a method to obtain accurate 3DUS-CT image registration for PBSI planning. Future work will focus on system validation and characterization in a clinical context as well as the assessment of impact on treatment plans. 相似文献